HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): John W. Brown Mark Ruzmetov Mark D. Rodefeld Mark W. Turrentine Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, J. W. Articles by Turrentine, M. W. Search for Related Content PubMed PubMed Citation Articles by Brown, J. W. Articles by Turrentine, M. W. Related Collections Valve disease

Ann Thorac Surg 2006;81:502-508
© 2006 The Society of Thoracic Surgeons

---

Original article: Cardiovascular

Mitral Valve Replacement With Ross II Technique: Initial Experience

Section of Cardiothoracic Surgery, James W. Riley Hospital for Children and Indiana University School of Medicine, Indianapolis, Indiana

Accepted for publication August 22, 2005.

^_* Address correspondence to Dr Brown, Section of Cardiothoracic Surgery, Indiana University School of Medicine, 545 Barnhill Drive, EH 215, Indianapolis, IN 46202-5123. (Email: jobrown{at}iupui.edu).

Presented at the Fifty-first Annual Meeting of the Southern Thoracic Surgical Association, Cancun, Mexico, Nov 2–4, 2004.

BACKGROUND: Pulmonary autograft mitral valve replacement (PA-MVR) was introduced clinically by Ross in 1967, but has been rarely utilized in North America and Europe. The aim of this study is to review our early experience with PA-MVR.

METHODS: Since June 2002, 8 patients (7 female and 1 male) between 12 to 46 years of age with outgrown mechanical valves (n = 3) failed MV repair for rheumatic or congenital MV disease (n = 4) and irreparable bileaflet myxoid prolapse (n = 1), underwent PA-MVR. The pulmonary autograft was harvested and replaced using a pulmonary homograft. The autografts were mounted within a woven Dacron graft 6–8 mm greater in diameter than the autograft annulus diameter on a preoperative echocardiogram. The graft's external surface was covered with fresh autologous pericardium.

RESULTS: There were no deaths. Intraoperative echocardiography confirmed a mean MV gradient of 4 mm Hg with trivial (n = 7) or mild (n = 1) regurgitation. Follow-up (range, 13 to 36 months) echocardiography in 4 patients showed no increase in MV gradient or regurgitation. One patient with severe myxoid degeneration and one patient with rheumatic disease, both with systemic hypertension, developed progressive regurgitation due to stretching of a single autograft leaflet producing prolapse. One patient developed a moderate gradient due to retention of excessive native mitral leaflet and subannular chordal tissue. Three of 4 patients have required PA-MVR replacement with mechanical valves 6 to 14 months post-PA-MVR. One asymptomatic patient with mild to moderate mitral regurgitation is being followed after treatment of her systemic hypertension.

CONCLUSIONS: Pulmonary autograft mitral valve replacement offers selected patients a potentially lifelong autologous valve without the need for long-term anticoagulation. The PA-MVR technique deserves careful consideration in younger patients in sinus rhythm. Postoperative systemic hypertension should be treated aggressively to prevent excessive stress on the pulmonary autograft particularly in the early postoperative months.

This article has been cited by other articles:

				T. P. Graham Jr The Year in Congenital Heart Disease J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2545 - 2553. [Full Text] [PDF]